Conv. Plasma
Nigella Sativa
Peg.. Lambda

All metformin studies
Meta analysis
Home COVID-19 treatment researchMetforminMetformin (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 20% Improvement Relative Risk Metformin for COVID-19  CORONADO  Prophylaxis Is prophylaxis with metformin beneficial for COVID-19? Retrospective 1,317 patients in France (March - April 2020) Lower mortality with metformin (not stat. sig., p=0.46) Cariou et al., Diabetologia, May 2020 Favors metformin Favors control

Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study

Cariou et al., Diabetologia, doi:10.1007/s00125-020-05180-x, CORONADO, NCT04324736
May 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
Analysis of 1,317 hospitalized COVID-19 patients with diabetes showing lower mortality with metformin use, without statistical significance.
risk of death, 20.0% lower, OR 0.80, p = 0.46, treatment 746, control 571, adjusted per study, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cariou et al., 29 May 2020, retrospective, France, peer-reviewed, mean age 69.8, 41 authors, study period 10 March, 2020 - 10 April, 2020, trial NCT04324736 (history) (CORONADO).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study
Bertrand Cariou, Samy Hadjadj, Matthieu Wargny, Matthieu Pichelin, Abdallah Al-Salameh, Ingrid Allix, Coralie Amadou, Gwénaëlle Arnault, Florence Baudoux, Bernard Bauduceau, Sophie Borot, Muriel Bourgeon-Ghittori, Olivier Bourron, David Boutoille, France Cazenave-Roblot, Claude Chaumeil, Emmanuel Cosson, Sandrine Coudol, Patrice Darmon, Emmanuel Disse, Amélie Ducet-Boiffard, Bénédicte Gaborit, Michael Joubert, Véronique Kerlan, Bruno Laviolle, Lucien Marchand, Laurent Meyer, Louis Potier, Gaëtan Prevost, Jean-Pierre Riveline, René Robert, Pierre-Jean Saulnier, Ariane Sultan, Jean-François Thébaut, Charles Thivolet, Blandine Tramunt, Camille Vatier, Ronan Roussel, Jean-François Gautier, Pierre Gourdy
Aims/hypothesis Coronavirus disease-2019 (COVID-19) is a life-threatening infection caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus. Diabetes has rapidly emerged as a major comorbidity for COVID-19 severity. However, the phenotypic characteristics of diabetes in COVID-19 patients are unknown. Methods We conducted a nationwide multicentre observational study in people with diabetes hospitalised for COVID-19 in 53 French centres in the period 10-31 March 2020. The primary outcome combined tracheal intubation for mechanical ventilation and/or death within 7 days of admission. Age-and sex-adjusted multivariable logistic regressions were performed to assess the prognostic value of clinical and biological features with the endpoint. ORs are reported for a 1 SD increase after standardisation. Results The current analysis focused on 1317 participants: 64.9% men, mean age 69.8 ± 13.0 years, median BMI 28.4 (25th-75th percentile: 25.0-32.7) kg/m 2 ; with a predominance of type 2 diabetes (88.5%). Microvascular and macrovascular diabetic complications were found in 46.8% and 40.8% of cases, respectively. The primary outcome was encountered in 29.0% (95% CI 26.6, 31.5) of participants, while 10.6% (9.0, 12.4) died and 18.0% (16.0, 20.2) were discharged on day 7. In univariate analysis, characteristics prior to admission significantly associated with the primary outcome were sex, BMI and previous treatment with renin-angiotensin-aldosterone system (RAAS) blockers, but not age, type of diabetes, HbA 1c , diabetic complications or glucoselowering therapies. In multivariable analyses with covariates prior to admission, only BMI remained positively associated with the primary outcome (OR 1.28 [1.10, 1.47]). On admission, dyspnoea (OR 2.10 [1.31, 3.35]), as well as lymphocyte count (OR A complete list of the CORONADO trial investigators is provided in the Electronic supplementary material (ESM).
Authors' relationships and activities BC reports grants and personal fees from Amgen, personal fees from AstraZeneca, personal fees from Akcea, personal fees from Genfit, personal fees from Gilead, personal fees from Eli Lilly, personal fees from Novo Nordisk, personal fees from MSD, grants and personal fees from Sanofi, and grants and personal fees from Regeneron. SH reports personal fees and non-financial support from AstraZeneca, grants and personal fees from Bayer, personal fees from Boehringer Ingelheim, grants from Dinno Santé, personal fees from Eli Lilly, non-financial support from LVL, personal fees and non-financial support from MSD, personal fees from Novartis, grants from Pierre Fabre Santé, personal fees and non-financial support from Sanofi, personal fees and non-financial support from Servier, and personal fees from Valbiotis. MP reports personal fees and non-financial support from Novo Nordisk, non-financial support from Sanofi, and non-financial support from Amgen. SB reports personal fees from Novo Nordisk, personal fees from Sanofi, personal fees from Eli Lilly, personal fees from Medtronic, and personal fees from Abbott. PD reports personal fees from Novo Nordisk, personal fees from Sanofi, personal fees from Eli Lilly, personal fees from MSD, personal fees from Novartis, personal fees from Abbott, personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, and personal fees from Mundipharma. BG reports personal fees from Eli Lilly, personal..
Alqahtani, Aleanizy, Hadi, Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study, Epidemiol Infect, doi:10.1017/S0950268818002923
Bhatraju, Ghassemieh, Nichols, Covid-19 in critically ill patients in the Seattle region -case series, N Engl J Med, doi:10.1056/NEJMoa2004500
Centre, St, Joseph -St, Luc, Lyon, Rennes, France 26 Département d'Endocrinologie et de Diabétologie
Drucker, Coronavirus infection and type 2 diabetes shared-pathways with therapeutic implications, Endocr Rev, doi:10.1056/NEJMsr2005760
Fosse-Edorh, Mandereau-Bruno, Piffaretti, Le poids du diabète en France en 2016 Synthèse épidémiologique. Santé p u b l i q u e F, doi:10.1056/NEJMoa011300
Garg, Kim, Whitaker, Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 -COVID-NET, 14 States, MMWR Morb Mortal Wkly Rep, doi:10.15585/mmwr.mm6915e3
Grasselli, Zangrillo, Zanella, Baseline characteristics and outcome of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy, JAMA, doi:10.1001/jama.2020.5394
Guan, Ni, Hu, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, doi:10.1056/NEJMoa2002032
Huang, Anthonius, Pranata, Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -a systematic review, meta-analysis, and metaregression, Diabetes Metab Syndr, doi:10.15585/mmwr.mm6913
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, Lancet, doi:10.1016/S0140-6736(20)30183-5
Kulcsar, Coleman, Beck, Frieman, Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection, JCI Insight, doi:10.1016/j.dsx.2020.04.018
Muller, Gorter, Hak, Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus, Clin Infect Dis, doi:10.1086/431587
Onder, Rezza, Brusaferro, Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy, JAMA, doi:10.1001/jama.2020.4683
Pornet, Bourdel-Marchasson, Lecomte, Trends in the quality of care for elderly people with type 2 diabetes: the need for improvements in safety and quality (the 2001 and 2007 ENTRED Surveys), Diabetes Metab, doi:10.1016/j.csda.2005.07.015
Roncon, Zuin, Rigatelli, Zuliani, Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome, J Clin Virol, doi:10.1016/j.jcv.2020.104354
Sauerbrei, Meier-Hirmer, Benner, Royston, Multivariable regression model building by using fractional polynomials: description of SAS, STATA and R programs, Comput Stat Data Anal, doi:10.1016/j.csda.2005.07.015
Schetz, Jong, Deane, Obesity in the critically ill: a narrative review, Intensive Care Med, doi:10.1002/oby.22831
Shah, Hux, Quantifying the risk of infectious diseases for people with diabetes, Diabetes Care, doi:10.2337/diacare.26.2.510
Simonnet, Chetboun, Poissy, High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation, Obesity, doi:10.1172/jci.insight.13177
Vaduganathan, Vardeny, Michel, Mcmurray, Pfeffer et al., Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19, N Engl J Med, doi:10.1007/s00134-019-05594-1
Van Den Berghe, Wouters, Weekers, Intensive insulin therapy in critically ill patients, N Engl J Med, doi:10.1210/endrev/bnaa011
Wu, Chen, Cai, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern Med, doi:10.1001/jamainternmed.2020.0994
Yang, Feng, Yuan, Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS, Diabet Med, doi:10.1111/j.1464-5491.2006.01861.x
Yang, Yu, Xu, Clinical course and outcomes of critically ill patients with SARS-CoV2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir Med, doi:10.1016/j.diabet.2011.02.001
Yang, Zheng, Gou, Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis, Int J Infect Dis, doi:10.1016/j.ijid.2020.03.01
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)305
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop